Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma

Kazuya Kariyama; Kazuhiro Nouso; Hidenori Toyoda; Toshifumi Tada; Atsushi Hiraoka; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Akiko Wakuta; Ayano Oonishi; Takashi Kumada; Masatoshi Kudo

doi:10.3390/cancers11020203

Related publications

Article2021

Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study

Tadatoshi Takayama, Shintaro Yamazaki, Yutaka Matsuyama, Yutaka Midorikawa, Shuichiro Shiina, Namiki Izumi, Kiyoshi Hasegawa, Norihiro Kokudo, Michiie Sakamoto, Shoji Kubo, Masatoshi Kudo, Takamichi Murakami, O Nakashima

Article2019

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Richard S. Finn, Masatoshi Kudo, Tim Meyer, Arndt Vogel, Michel Ducreux, Teresa Macarulla, Gianluca Tomasello, Frédéric Boisserie, Jeannie Hou, Xin Li, James Song, Andrew X. Zhu

Article2010

New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers

Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savić, Helena Cornellà, Josep M. Llovet

Clinical Cancer Research

Article2018

The prognostic value of prognostic nutritional index in hepatocellular carcinoma patients: A meta-analysis of observational studies

Zhong Lin Wang, Jie Wang, Peijun Wang

Article2011

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma

Josep M. Llovet, Valérie Paradis, Masatoshi Kudo, Jessica Zucman‐Rossi

Liver Transplantation